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INTRODUCTION: 21-hydroxylase deficiency is an autosomal recessive disorder that causes glucocorticoid deficiency
and increased androgen production. Treatment is based on glucocorticoid replacement; however, interindividual
variability in the glucocorticoid dose required to achieve adequate hormonal control has been observed.
OBJECTIVE: The present study aimed to evaluate the association between polymorphic variants involved in
glucocorticoid action and/or metabolism and the mean daily glucocorticoid dose in 21-hydroxylase deficiency
patients.
METHODS:We evaluated 53 patients with classical forms of 21-hydroxylase deficiency who were receiving cortisone
acetate. All patients were between four and six years of age and had normal androgen levels.
RESULTS: The P450 oxidoreductase A503V, HSD11B1 rs12086634, and CYP3A7*1C variants were found in 19%,
11.3% and 3.8% of the patients, respectively. The mean¡SD glucocorticoid dose in patients with the CYP3A7*1C
and wild-type alleles was 13.9¡0.8 and 19.5¡3.2 mg/m2/d, respectively. We did not identify an association between
the P450 oxidoreductase or HSD11B1 allelic variants and the mean glucocorticoid dose.
CONCLUSION: Patients carrying the CYP3A7*1C variant required a significantly lower mean glucocorticoid dose.
Indeed, the CYP3A7*1C allele accounted for 20% of the variability in the cortisone acetate dose. The analysis of
genes involved in glucocorticoid metabolism may be useful in the optimization of treatment of 21-hydroxylase
deficiency.
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INTRODUCTION
Congenital adrenal hyperplasia (CAH) due to 21-hydro-
xylase deficiency is a common autosomal recessive disorder,
caused by mutations in the 21-hydroxylase gene (CYP21A2).
These mutations result in decreased glucocorticoid (GC)
secretion with or without mineralocorticoid deficiency and
excess androgens.1,2
GC replacement therapy significantly improves the
prognosis of CAH. The goal of GC replacement therapy is
to restore the levels of the steroid hormones to the normal
range and to decrease adrenocorticotrophic stimulation,
which would suppress the effects of androgen overproduc-
tion. The aims of GC replacement are to avert adrenal crisis
and to allow normal growth and puberty development.
Similarly, mineralocorticoid replacement restores serum
electrolyte levels and water balance without excessive salt
retention.
During growth, preference is given to short half-life
glucocorticoids (e.g., hydrocortisone acetate) that avoid
growth suppression and weight gain, which are commonly
observed when long half-life GCs (e.g., prednisone or
dexamethasone) are used.1 Among the GCs with a short
half-life, cortisone acetate (CA) is one therapeutic option for
the treatment of children with CAH.3 Cortisone acetate is
converted to cortisol by the action of 11b-hydroxysteroid
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dehydrogenase type 1 (11bHSD1); however, variability in
11bHSD1 activity has been described.4
Despite great advances in our understanding of the
pathophysiology of CAH, most studies still report mean
final heights in CAH patients under 21.5 Standard
Deviation (SD).5 These shorter heights also reflect the
difficulties in treatment compliance and the complexity of
GC dose adjustments to balance cortisol insufficiency and
androgen overproduction.
Furthermore, the interindividual variability in daily
glucocorticoid dose requirements poses an additional
challenge in the treatment of CAH8 and suggests that
genetic factors may modulate the glucocorticoid response.
In the treatment of Addison’s disease, genetic factors play a
major role in the differential response to glucocorticoid
replacement regimens and/or the incidence of side effects.9
However, genetic factors have never been evaluated in
CAH, which led us to hypothesize that interindividual
variability in glucocorticoid metabolism could be involved.
The CYP3A family of enzymes is the most important
family of enzymes for drug metabolism in humans because
they metabolize the majority of commercially available
drugs. Many studies have shown that polymorphisms in
CYP3A genes account for interindividual variability in the
metabolism of many clinically used drugs.10 The CYP3A7
gene, which encodes P4503A7, is abundantly expressed in the
fetal liver, and its expression declines rapidly after birth. The
polymorphic variant CYP3A7*1C, which results from the
replacement of an approximately 60-bp sequence within the
promoter of CYP3A7 with an analogous region of the
CYP3A4 promoter, leads to persistent P4503A7 expression
in the adult liver11 and has been associated with lower serum
dehydroepiandrosterone sulfate (DHEAS) and testosterone
levels compared with the levels in individuals lacking this
variant.12 Because of the presence of lower androgen levels,
we speculated that the CYP3A7*1C allele may decrease the
glucocorticoid requirement in CAH patients.
The 11bHSD1 enzyme is involved in glucocorticoid
metabolism by converting inactive cortisone into active
cortisol.13 A polymorphism located in intron 3 (rs12086634)
has been associated with decreased conversion of cortisone
to cortisol and may function as an intronic enhancer.14
Therefore, CAH patients with this polymorphism could
require higher CA doses compared with patients lacking
this polymorphism.
Finally, the P450 oxidoreductase (POR) gene encodes a
flavoprotein that donates electrons to cytochrome P450 type
II enzymes, including P450c21 and P450c17. A frequent POR
variant (A503V) has been associated with reduced P450c17
activity and, consequently, with lower androgen secretion.15
Because of the critical role of this polymorphism in steroid
hormone production, we hypothesized that it could reduce
the glucocorticoid requirement in CAH patients.
Therefore, the aim of the present study was to investigate
whether interindividual variability in glucocorticoid require-
ments amongst treated CAH patients is influenced by the
presence of polymorphisms in CYP3A7, POR or HSD11B1.
SUBJECTS AND METHODS
Subjects
The present study was approved by the Ethic Committee of
the Faculdade de Medicina da Universidade de Sa˜o Paulo,
and written consent was obtained from patients and controls.
The medical records of 53 patients with CAH were
reviewed from a group of 213 classical CAH patients who
underwent glucocorticoid replacement therapy in our
hospital. The selection criteria included the use of CA, good
compliance and hormonal control between the ages of 4 and
6 years (before starting pubertal development). Adequate
control was defined by normal auxological parameters and
biochemical assessments according to age during the two
years of this study. The assessment comprised eight
laboratory measurements.
Testosterone and androstenedione levels were main-
tained at levels lower than 0.48 nmol/l (14 ng/dl) and
69.9 pmol/L (2 ng/ml), respectively. Bone age was evalu-
ated yearly using the Greulich-Pyle system. No patient
presented with adrenal crisis during this period or clinical/
hormonal parameters suggestive of overtreatment (e.g.,
Cushing features, decreased growth rate or 17-hydroxypro-
gesterone levels less than 36 nmol/l).
Thirty-eight patients (27 females) had the salt-wasting
(SW) form, which was defined as the development of
dehydration, a sodium level less than 130 mmol/l and high
plasmatic renin activity in the neonatal period. Fifteen
patients (11 females) had the simple virilizing (SV) form,
which was characterized by ambiguous genitalia in girls and
signs of postnatal virilization in both sexes without dehydra-
tion or salt waste. At diagnosis, all patients had basal 17-
hydroxyprogesterone levels that were greater than 50 ng/ml.
Daily CA doses (mg/m2/day) were evaluated retro-
spectively. The CA doses were administered three times a
day, and the highest dose was administered at bedtime.
Patients with the SW form also received fludrocortisone
50¡25 mg/day in the morning. No patient received gona-
dotropin-releasing hormone analogs, aromatase inhibitors
or anticonvulsants.
Body mass index (BMI) was calculated as the weight (in
kilograms) divided by the height (in meters) squared, and
the BMI Z-score was determined according to the curves of
the Centers for Disease Control and Prevention. Of the 53
patients, 13 achieved final height (FH). The relationship
between the achieved FH and target height (TH) is
expressed as FH.SDS - TH.SDS, and this value was
individually calculated for each patient.
Methods
CYP21A2 mutations were screened by Southern blotting
to identify large gene rearrangements and by allele-specific
polymerase chain reaction (PCR) to determine the 15
common microconversions.16 If mutations were not identi-
fied in both alleles, CYP21A2 sequencing was performed.
The identified mutations were segregated in parent DNA
samples. CYP21A2 genotypes were divided according to
predicted impairment of enzymatic activity as previously
described: null and A and B groups, prediciting 0%, 2% and
3–7% residual enzymatic activity, respectively .1
Selected regions of the CYP3A7, POR, and HSD11B1 genes
were amplified and sequenced as previously described.11,15,17
One hundred healthy volunteers were selected to determine
the allelic frequency of the identified polymorphisms. None
of the control subjects had a history of malignancy.
Statistical Analyses
Qualitative variables are listed as frequencies and percen-
tages, whereas quantitative variables are presented as the
mean¡SD. Group comparisons based on genotype were
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performed using an unpaired Student t-test or a Mann-
Whitney rank sum test for numerical variables and a Chi-
square or Fisher exact test for nominal variables, as appro-
priate. To assess whether the genetic variants had indepen-
dent prognostic significance for outcome, we performed
single regression analysis followed by multiple regression
analysis adjusting for established influential factors. A p-value
less than 0.05 was considered statistically significant.
RESULTS
The POR A503V, HSD11B1 rs12086634, and CYP3A7*1C
polymorphic variants were found in 19%, 11.3%, and 3.8% of
the CAH patients and in 26.4%, 17.4%, and 2.3% of the control
subjects, respectively. The CYP3A7*1C and POR variants
were identified only in heterozygous state in the studied
patients. In contrast, 1% of the CAH patients and 6% of the
controls were homozygous for the HSD11B1 rs12086634
allele, whereas 10.3% of the CAH patients and 12% of the
controls were heterozygous. The frequency of these genetic
variants did not differ between children with CAH and the
controls (p.0.05). All polymorphisms were in Hardy-
Weinberg equilibrium.
In patients between 4 and 6 years of age with the SW
and SV forms, the mean CA dose was 18.5¡3.4 and
20.1¡3.3 mg/m2/day, respectively (p= 0.086). In SW
patients between 4 and 6 years of age, the mean fludro-
cortisone dose was 50¡25 mg/day. There were no differ-
ences in the mean CA doses among patients with the null, A
or B CYP21A2 genotypes (p.0.05).
In the period of this study, the mean bone age advance-
ment in SW and SV patients was 1.5¡0.7 and 1.2¡0.6 years,
respectively (p.0.05). The mean BMI Z-scores at 4 and 6
years of age were 0.8¡0.003 and 0.7¡¡0.02, respectively.
In addition, the mean 17-hydroxyprogesterone levels during
these two years were 194.8¡157.6 nmol/l (6,283¡5,063 ng/
dl) and 202.7¡132.8 nmol/l (6,540¡4,285 ng/dl) in
patients with SW and SV forms, respectively. Of the 53
patients, 13 achieved FH, and the corrected FH ranged from
20.87 to +0.86 SD. The clinical data are described in Table 1.
There were no differences in the mean daily CA doses
between the patients with the wild-type POR allele and the
patients heterozygous for the POR A503V allele or between
the patients with the wild-type HSD11B1 allele and the
patients heterozygous or homozygous for the HSD11B1
rs12086634 allele (Table 2).
Interestingly, the mean daily CA dose was lower in
patients with the CYP3A7*1C allele compared with patients
with the wild-type allele: 13.9¡0.8 vs. 19.5¡3.2 mg/m2/d,
respectively (95% confidence interval for difference of
means: 2.4 to 8.8 mg/m2/d; p= 0.001, power of calculation
96.2%). Moreover, single regression analysis followed by
multiple linear regression analysis revealed that the
influence of this polymorphism on CA dose did not vary
according to clinical form, sex, CYP21A2 genotype or
concomitant use of fludrocortisone. The CYP3A7*1C variant
alone accounted for 20% of the CA dose variability
(p= 0.001), and 33% of the observed variability was
explained by the presence of CYP3A7*1C in association
with the age at diagnosis (p= 0.004).
DISCUSSION
A short FH and adverse effects have been described
during CAH treatment despite the achievement of adequate
hormonal control. Several approaches have been proposed
to improve treatment, such as the addition of flutamide and
testolactone to glucocorticoid replacement therapy18 and
therapy optimization strategies based on CYP21A2 geno-
types.19 Although a good correlation has been observed
between genotype and the clinical form, no such correlation
has been identified between genotype and glucocorticoid
requirements in classical forms.19 Similarly, in our cohort,
there were no differences in the mean glucocorticoid dose
among patients with null, A, or B CYP21A2 genotypes,
which suggests that other factors influence the glucocorti-
coid requirement.
To investigate these factors, we chose to evaluate the
glucocorticoid dose in patients between 4 and 6 years of age,
which appears to be a period of steady linear growth.
Several studies have shown a tendency to overtreat in the
first three years of life to avoid SW crises. During puberty,
however, the glucocorticoid requirement generally increases
because of alterations in cortisol pharmacokinetics.20
Despite suppressed androgen levels, we ruled out over-
treatment in our cohort because the serum 17-hydroxypro-
gesterone levels were greater than 36 nmol/l, and the mean
BMI Z-score and mean growth rate of all patients were both
in the normal range.
Genetic factors have been shown to contribute to inter-
individual variability in the response to different drugs.10
Recently, genetic polymorphisms have been associated with
Table 1 - Clinical, auxological and hormonal data of 53
patients with CAH.
SW patients SV patients
Female/Male 27/11 11/4
Age at diagnosis (y) 0.2¡0.8 2.9¡1.7
Mean bone age (y) at diagnosis - 5.8¡4.5
Basal 17OHP (mmol/L) levels at diagnosis 303¡341 199¡166
Mean daily CA doses (mg/m2/day) 18.5¡3.4 20.1¡3.3
Fludrocortisone ( mg/day) 50¡25 -
Mean BMI at 4 y (kg/m2) 17.1¡2.1 16.2¡1.3
Mean BMI at 6 y (kg/m2) 16.2¡1.6 17.6¡2.7
Mean BMI at 4 y (SDU)1 1.0¡0.9 0.6¡0.8
Mean BMI at 6 y (SDU)1 1.0¡1.1 0.4¡0.8
Height SDS for bone age at 4 y 0.02 0.9
Height SDS for bone age at 6 y 0.16 1.3
Final height SDS** 21.4¡1.4 21.0¡0.9
Target height SDS 20.9¡1.0 20.6¡1.2
SW: salt-wasting form, SV: simple virilizing form, CA: cortisone acetate
dose used from 4–6 y of age.
Values are presented as the mean¡SD.
**13/53 patients achieved final height.
1SDU scores are the number of SD units relative to the mean values for
normal children of the same age and sex.
Table 2 - Mean¡SD daily cortisone acetate doses (mg/m2/
day) according to genetic polymorphisms in patients with
classical 21-hydroxylase deficiency.
Allelic Variant Genotype CA dose (mg/m2/d) p-value
HSD11B1 C/C 19.1¡3.6 0.852
(rs12086634) C/T 19.3¡2.7
CYP3A7 Wild type 19.5¡3.2 ,0.001
(CYP3A7*1C) CYP3A7*1C 13.9¡0.8
POR C/C 19.2¡3.5
(A503V) C/T 18.7¡3.4 0.569
CA: cortisone acetate.
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variability in glucocorticoid doses and susceptibility to
osteoporosis in Addison’s disease.9 Among treated CAH
patients, there is great interindividual variability in the daily
glucocorticoid dose. To the best of our knowledge, however,
there are no data evaluating the effect of allelic variants other
than CYP21A2 gene variants.
The frequency of the POR A503V, HSD11B1 rs12086634,
and CYP3A7*1C allelic variants was similar among patients
and controls in our study. Although POR A503V is
associated with decreased P450c17 activity and decreased
androgen synthesis, our data suggest that this enzymatic
impairment, at least in the heterozygous individuals seen in
our cohort, does not influence the daily CA requirement.
Interestingly, the HSD11B1 rs12086634 variant has been
shown to reduce gene transcription in vitro, which was
consistent with reduced cortisol generation and probably
higher CA requirements.14 In our cohort, however,
HSD11B1 rs12086634 carriers required a CA dose similar
to that required by individuals lacking this variant.
The CYP3A7 gene is predominantly expressed in the fetal
liver, and its expression is sharply downregulated after
birth.11 However, the CYP3A7*1C allele contains a modified
promoter that causes constitutive CYP3A7 expression in the
adult liver.21 P4503A7 catalyzes the 16a-hydroxylation of
DHEA and DHEAS22, and the CYP3A7*1C allele has been
associated with lower DHEAS levels in women with
polycystic ovary syndrome.12 Although the allelic frequency
of this genetic variant did not differ between the children
with CAH and the controls, the glucocorticoid replacement
doses were significantly lower in children with the
CYP3A7*1C allele.
Because CAH treatment is designed to normalize andro-
gens, we hypothesized that the CYP3A7*1C allele results in
less severe hyperandrogenism and, consequently, decreased
glucocorticoid requirements. However, the CYP3A7*1C
allele was a rare variant in our Brazilian cohort and
probably only affects the treatment of a minority of patients.
There is no doubt that other variants in different genes,
such as those related to gastrointestinal absorption, could
contribute to the interindividual variability in glucocorticoid
doses.
We cannot exclude a sample-size effect to explain the
absence of a correlation between the POR and HSD11B1
variants and the mean daily glucocorticoid dose. This was a
pilot study involving a large series of Brazilian patients
followed at a single center, and we were able to select 53
patients who were treated with the same glucocorticoid (i.e.,
CA) since their diagnosis.
Despite the limitations of this study design, other retro-
spective studies have also highlighted the influence of
pharmacogenetics on individual responses to drugs.23,24
Indeed, pharmacogenetic testing has become an important
tool to guide therapy with drugs such as warfarin, dasatinib
and trastuzumab.25
The present study is the first to raise the potential
advantage of genetic screening to obtain better CAH
treatment. Future studies involving both larger cohorts
and other candidate genes are certainly warranted to
consolidate this approach.
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